Delayed Graft Function Phenotypes and 12-Month Kidney Transplant Outcomes.

Transplantation

1 Division of Nephrology, Hypertension & Renal Transplantation, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT. 2 Renal-Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, PA. 3 Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, PA. 4 Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA. 5 Division of Nephrology, Department of Medicine, Wayne State University, Detroit, MI. 6 Saint Barnabas Medical Center, Livingston, NJ. 7 Section of Nephrology, University Hospital, Ulm, Germany. 8 Section of Nephrology, Yale University School of Medicine, New Haven, CT. 9 Program of Applied Translational Research, Department of Medicine, Yale University School of Medicine, New Haven, CT. 10 Veterans Affairs Connecticut Healthcare System, New Haven, CT.

Published: August 2017

Background: Ischemia-reperfusion injury (IRI) leading to delayed graft function (DGF), defined by the United Network for Organ Sharing as dialysis in the first week (UNOS-DGF), associates with poor kidney transplant outcomes. Controversies remain, however, about dialysis initiation thresholds and the utility for other criteria to denote less severe IRI, or slow graft function (SGF).

Methods: Multicenter, prospective study of deceased-donor kidney recipients to compare UNOS-DGF to a definition that combines impaired creatinine reduction in the first 48 hours or greater than 1 dialysis session for predicting 12-month estimated glomerular filtration rate (eGFR). We also assessed 10 creatinine and urine output-based SGF definitions relative to 12-month eGFR.

Results: In 560 recipients, 215 (38%) had UNOS-DGF, 330 (59%) met the combined definition, 14 (3%) died, and 23 (4%) had death-censored graft failure by 12 months. Both DGF definitions were associated with lower adjusted 12-month eGFR (95% confidence interval)-by 7.3 (3.6-10.9) and 7.4 (3.8-11.0) mL/min per 1.73 m, respectively. Adjusted relative risks for 12-month eGFR less than 30 mL/min per 1.73 m were 1.9 (1.2-3.1) and 2.1 (1.1-3.7), with unadjusted areas under the curve of 0.618 and 0.627, respectively. For SGF definitions, postoperative day (POD) 7 creatinine had the strongest association with 12-month eGFR, and POD5 creatinine and creatinine reduction between POD1 and POD2 demonstrated modest separations in 12-month eGFR.

Conclusions: Although UNOS-DGF does not adequately predict 12-month function on its own, our findings do not support changing the definition. Postoperative day 7 creatinine is correlated with 12-month eGFR, but large translational studies are needed to understand the biological link between IRI severity at transplant and longer-term outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292094PMC
http://dx.doi.org/10.1097/TP.0000000000001409DOI Listing

Publication Analysis

Top Keywords

12-month egfr
16
graft function
12
12-month
9
delayed graft
8
kidney transplant
8
transplant outcomes
8
creatinine reduction
8
sgf definitions
8
ml/min 173
8
postoperative day
8

Similar Publications

PURPOSE EXONERATE (EXOsome and cell-free micro-RNAs of anti-EGFR ResistAnce) was an open-label, biomarker interventional study designed to develop, test, and validate a liquid biopsy predictive of progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) for first-line EGFR inhibitors in metastatic colorectal cancer (mCRC). PATIENTS AND METHODS Patients with newly diagnosed RAS-WT, chemotherapy-naïve mCRC, both right- and left-sided, were enrolled in 2-nationwide trials to receive cetuximab or panitumumab along with chemotherapy. The primary endpoint was 12-month PFS, which was hierarchically tested in left- and right-sided mCRC to predict PFS, OS, and ORR.

View Article and Find Full Text PDF

Donor-derived cell-free DNA (dd-cfDNA) in the peripheral blood of allograft recipients has shown to early identify allograft injury. In this study, we assessed the factors that influence the amount of circulating dd-cfDNA during the first month postkidney transplant as well as its longitudinal trend. A consecutive series of 98 adult kidney transplant recipients at a single center between July 2018 and January 2020 were included in this study.

View Article and Find Full Text PDF

Background: The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment.

Methods: We conducted an open-label, single-arm, multicenter, phase II trial in China. Eligible patients were 18-75 years old with histologically or cytologically confirmed NSCLC who were EGFR mutation positive and showed gradual, oligo, or potential progression after EGFR-TKIs.

View Article and Find Full Text PDF

Machine Learning Models to Predict Bone Metastasis Risk in Patients With Lung Cancer.

Cancer Med

November 2024

Department of Orthopaedics and Traumatology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.

Article Synopsis
  • The study aimed to identify key variables for machine learning algorithms to predict which lung cancer patients are at high risk for bone metastasis.
  • A total of 1864 lung cancer patients were analyzed, considering 25 risk factors, with results indicating that specific features like AJCC staging and the use of EGFR inhibitors significantly raise the risk of bone metastasis, while older age lowers it.
  • The developed machine learning model can be integrated into clinical systems to provide real-time predictions, helping clinicians tailor treatment plans for their patients based on the metastatic risk assessment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!